Results 231 to 240 of about 82,620 (274)
A Rare Case of Chronic Lymphocytic Leukemia Transforming Into Waldenström Macroglobulinemia During Ibrutinib Therapy. [PDF]
Samsuddoha K, Homsy S, Preet M, Naher K.
europepmc +1 more source
Nanomedicine Approaches for Autophagy Modulation in Cancer Therapy
Autophagy modulation holds promise for enhancing cancer treatment, yet clinical translation remains challenging. This review explores nanomedicine‐based strategies to improve autophagy‐targeting drugs, highlighting their synergy with chemotherapy, immunotherapy, phototherapy, and gene therapy. It also discusses nanoparticle design and clinical progress,
Sohaib Mahri+11 more
wiley +1 more source
Real world outcomes with Ibrutinib monotherapy in chronic lymphocytic leukemia: a single center experience. [PDF]
Mesaros O+10 more
europepmc +1 more source
Fire‐related smoke inhalation‐induced acute lung injury (SI‐ALI) poses a significant public health risk, yet effective treatments are limited due to the lack of suitable models. This study developed a more realistic model of SI‐ALI using organ‐on‐a‐chip and organoid technologies, identified key molecules such as catechol‐O‐methyltransferase and ...
Junmin Li+12 more
wiley +1 more source
Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link? [PDF]
Ayoub M, Susin SA, Bauvois B.
europepmc +1 more source
Abstract Two cases of sporadic multicentric lymphomas with mediastinal masses in goats are documented. The first case involved a 3.5‐year‐old male goat. Ultrasound imaging revealed an enlarged right perirenal lymph node, which was confirmed as lymphoma through incisional biopsy and cytopathological analysis. Despite treatment, the goat succumbed to the
Angélica Consalter+6 more
wiley +1 more source
Extramedullary and extranodal manifestations in chronic lymphocytic leukemia - an update. [PDF]
Robak T, Puła A, Braun M, Robak E.
europepmc +1 more source
SCF and TSLP expression are known to drive unique immune responses leading to the onset of allergic and inflammatory diseases. Here, we describe the characterization of a novel bsAb, CDX‐622, that targets SCF and TSLP. CDX‐622 inhibits MC functions through SCF starvation and Type 2 inflammatory responses via TSLP inhibition.
Michael B. Murphy+17 more
wiley +1 more source
BCL2i-Based Therapies and Emerging Resistance in Chronic Lymphocytic Leukemia. [PDF]
Li WF, Atalla E, Dong J, Konopleva M.
europepmc +1 more source